生物与非生物抗风湿药对类风湿关节炎贫血指标的真实世界疗效
基于美国电子病历的真实世界研究纳入153,788例类风湿关节炎患者,比较托珠单抗、托法替布、其他生物DMARD和其他非生物DMARD对血红蛋白和红细胞压积的影响。托珠单抗组24个月时Hb和Hct显著升高,贫血患者升高更明显,且Hb≥1g/dL升高的可能性较其他组高86%。早期启动托珠单抗者6个月内Hb升高可能性更高。
要点
- 托珠单抗治疗24个月Hb平均升高0.23g/dL,Hct升高0.96%。
- 托珠单抗组贫血患者Hb升高0.72g/dL,Hct升高2.06%。
- 早期启动托珠单抗者6个月内Hb升高可能性更高。
核心结论
- 真实世界研究提示托珠单抗治疗可显著升高类风湿关节炎患者的Hb和Hct水平。
- 托珠单抗组Hb≥1g/dL升高的可能性较其他DMARDs合并组高86%。
- 其他生物或非生物DMARDs组未观察到有临床意义的Hb变化。
研究设计与样本
- 使用美国Centricity电子病历,纳入2000年1月至2016年4月诊断的类风湿关节炎患者。
- 患者启动托珠单抗(n=3732)、托法替布(n=3126)、其他生物DMARD(n=55964)或其他非生物DMARD(n=91236)。
- 评估治疗启动后2年内Hb和Hct变化,并校正和平衡混杂因素。
主要发现
- 托珠单抗组24个月校正后Hb平均升高0.23g/dL(95%CI 0.14,0.42),Hct升高0.96%(95%CI 0.41,1.52)。
- 托珠单抗组贫血患者Hb升高0.72g/dL,Hct升高2.06%。
- 托珠单抗组Hb≥1g/dL升高的OR为1.43-2.00,即较其他组合并高86%。
- 其他生物DMARD组Hct升高低于托珠单抗组,其余组无显著变化。
- 诊断1年内启动托珠单抗者6个月内Hb升高的OR=1.95(95%CI 1.19,3.21;p<0.001)。
关键数值与推荐
- 托珠单抗组24个月Hb平均升高0.23g/dL(95%CI 0.14,0.42)。
- 托珠单抗组24个月Hct平均升高0.96%(95%CI 0.41,1.52)。
- 托珠单抗组贫血患者Hb升高0.72g/dL,Hct升高2.06%。
- 托珠单抗组Hb≥1g/dL升高的OR 95%CI为1.43-2.00。
- 早期启动托珠单抗者6个月内Hb升高的OR=1.95(95%CI 1.19,3.21;p<0.001)。
临床怎么用
- 对类风湿关节炎合并贫血患者,托珠单抗可能改善Hb和Hct指标。
- 托珠单抗对贫血指标的改善优于其他生物和非生物DMARDs。
- 早期启动托珠单抗可能更有利于Hb的短期改善。
局限性
- 本研究为真实世界电子病历分析,非随机对照试验。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To evaluate the impact of treatment with disease-modifying antirheumatic drugs (DMARDs), including IL-6 receptor inhibitor tocilizumab (TCZ), on anaemia markers in patients with rheumatoid arthritis. METHODS: Using the Centricity Electronic Medical Records from USA, patients with rheumatoid arthritis diagnosed between January 2000 and April 2016, who initiated TCZ (n = 3732); tofacitinib (TOFA, n = 3126); other biologic DMARD (obDMARD, n = 55,964); or other non-biologic DMARD (onbDMARD, n = 91,236) were identified. Changes in haemoglobin (Hb) and haematocrit (Hct) over 2 years of treatment initiation were evaluated, adjusting and balancing for confounders. RESULTS: Mean (95% CI) adjusted increase in Hb and Hct levels at 24 months in TCZ group were 0.23g/dL (0.14, 0.42) and 0.96% (0.41, 1.52) respectively. Among patients with anaemia in the TCZ group, Hb and Hct increased significantly by 0.72g/dL and 2.06%, respectively. Patients in the TCZ group were 86% (95% CI of OR: 1.43, 2.00) more likely to increase Hb ≥ 1g/dL compared to the other groups combined. No clinically significant changes in Hb were observed in the other groups. The obDMARD group demonstrated lower Hct increase than TCZ group, while no significant changes were observed in the remaining groups. Compared to those who initiated TCZ therapy after 1 year of diagnosis of rheumatoid arthritis, those who initiated earlier were 95% (OR = 1.95; 95% CI: 1.19, 3.21; p < 0.001) more likely to increase Hb within 6 months. CONCLUSIONS: This real-world study suggests significant increase in Hb and Hct levels after TCZ therapy in anaemic and non-anaemic patients with rheumatoid arthritis, compared with other biologic and non-biologic DMARDs.
引用
- Paul SK, Montvida O, Best JH, et al. Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: New evidence from real-world data. Semin Arthritis Rheum. 2017. PMID: 28947313. doi:10.1016/j.semarthrit.2017.08.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。